Concurrent use of opioids with benzodiazepines or nonbenzodiazepine sedatives among patients with cancer referred to an outpatient palliative care clinic.
Analgesics, Opioid
/ administration & dosage
Benzodiazepines
/ administration & dosage
Cancer Pain
/ drug therapy
Combined Modality Therapy
/ adverse effects
Drug Overdose
/ epidemiology
Female
Humans
Hypnotics and Sedatives
/ administration & dosage
Male
Middle Aged
Neoplasms
/ complications
Outpatients
Palliative Care
/ methods
benzodiazepines
nonbenzodiazepine sedatives
opioid
palliative care
polypharmacy
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 Dec 2019
15 Dec 2019
Historique:
received:
05
03
2019
revised:
10
07
2019
accepted:
02
08
2019
pubmed:
29
8
2019
medline:
27
5
2020
entrez:
29
8
2019
Statut:
ppublish
Résumé
The concurrent use of opioids with benzodiazepines (BZD) or nonbenzodiazepine sedatives (S) recently was found to be associated with an increased risk of overdose death compared with the use of opioids alone. In the current study, the authors examined the frequency and trend of concurrent opioid/BZD-S use and its associated risk factors among patients with cancer. Data regarding the frequency and trend of concurrent opioid/BZD-S use were extracted for 1500 randomly selected patients referred to the outpatient palliative care clinic at The University of Texas MD Anderson Cancer Center between the calendar years of 2011 and 2016. To explore associated risk factors, the authors compared the demographic and clinical predictors of 418 patients each in the concurrent opioid/BZD-S group and opioids-only group. In 2011, at the time of referral to the palliative care clinic, 96 of 221 patients with cancer (43%) were prescribed concurrent opioids/BZD-S. This rate progressively declined to 67 of 217 patients (31%) by 2016 (P = .0008). Patients in the concurrent opioid/BZD-S group had a higher percentage of females (233 individuals; 55% [P = .007]) and whites (323 individuals; 77% [P = .002]), and patients reported higher scores regarding depression (P = .0001), anxiety (P ≤ .0001), drowsiness (P = .048), and worst feeling of well-being (P = .001). The morphine equivalent daily dose was significantly higher in concurrent opioid/BZD-S group (median of 67.5 mg/day [interquartile range (IQR), 30-135 mg/day] vs 60 mg/day [IQR, 30-105 mg/day]; P = .034). Multivariate analysis demonstrated that anxiety (P ≤ .0001), white race (P = .0092), and poor Eastern Cooperative Oncology Group performance status (P = .0017) were significantly associated with concurrent use. The concurrent use of opioids with BZD-S has declined but continues to be frequent among patients with cancer. Anxiety, white race, and poor Eastern Cooperative Oncology Group performance status were associated with its use. More research is needed to explore which medications can replace these agents.
Sections du résumé
BACKGROUND
BACKGROUND
The concurrent use of opioids with benzodiazepines (BZD) or nonbenzodiazepine sedatives (S) recently was found to be associated with an increased risk of overdose death compared with the use of opioids alone. In the current study, the authors examined the frequency and trend of concurrent opioid/BZD-S use and its associated risk factors among patients with cancer.
METHODS
METHODS
Data regarding the frequency and trend of concurrent opioid/BZD-S use were extracted for 1500 randomly selected patients referred to the outpatient palliative care clinic at The University of Texas MD Anderson Cancer Center between the calendar years of 2011 and 2016. To explore associated risk factors, the authors compared the demographic and clinical predictors of 418 patients each in the concurrent opioid/BZD-S group and opioids-only group.
RESULTS
RESULTS
In 2011, at the time of referral to the palliative care clinic, 96 of 221 patients with cancer (43%) were prescribed concurrent opioids/BZD-S. This rate progressively declined to 67 of 217 patients (31%) by 2016 (P = .0008). Patients in the concurrent opioid/BZD-S group had a higher percentage of females (233 individuals; 55% [P = .007]) and whites (323 individuals; 77% [P = .002]), and patients reported higher scores regarding depression (P = .0001), anxiety (P ≤ .0001), drowsiness (P = .048), and worst feeling of well-being (P = .001). The morphine equivalent daily dose was significantly higher in concurrent opioid/BZD-S group (median of 67.5 mg/day [interquartile range (IQR), 30-135 mg/day] vs 60 mg/day [IQR, 30-105 mg/day]; P = .034). Multivariate analysis demonstrated that anxiety (P ≤ .0001), white race (P = .0092), and poor Eastern Cooperative Oncology Group performance status (P = .0017) were significantly associated with concurrent use.
CONCLUSIONS
CONCLUSIONS
The concurrent use of opioids with BZD-S has declined but continues to be frequent among patients with cancer. Anxiety, white race, and poor Eastern Cooperative Oncology Group performance status were associated with its use. More research is needed to explore which medications can replace these agents.
Substances chimiques
Analgesics, Opioid
0
Hypnotics and Sedatives
0
Benzodiazepines
12794-10-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4525-4531Informations de copyright
© 2019 American Cancer Society.
Références
Yennurajalingam S, Kwon JH, Urbauer DL, Hui D, Reyes-Gibby CC, Bruera E. Consistency of symptom clusters among advanced cancer patients seen at an outpatient supportive care clinic in a tertiary cancer center. Palliat Support Care. 2013;11:473-480.
Delgado-Guay M, Ferrer J, Rieber AG, et al. Financial distress and its associations with physical and emotional symptoms and quality of life among advanced cancer patients. Oncologist. 2015;20:1092-1098.
Hui D, Karuturi MS, Tanco KC, et al. Targeted agent use in cancer patients at the end of life. J Pain Symptom Manage. 2013;46:1-8.
Kroschinsky F, Stolzel F, von Bonin S, et al; Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017;21:89.
Kotlinska-Lemieszek A, Paulsen O, Kaasa S, Klepstad P. Polypharmacy in patients with advanced cancer and pain: a European cross-sectional study of 2282 patients. J Pain Symptom Manage. 2014;48:1145-1159.
LeBlanc TW, McNeil MJ, Kamal AH, Currow DC, Abernethy AP. Polypharmacy in patients with advanced cancer and the role of medication discontinuation. Lancet Oncol. 2015;16:e333-e341.
White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction. 1999;94:961-972.
Griffin CE 3rd, Kaye AM, Bueno FR, Kaye AD. Benzodiazepine pharmacology and central nervous system-mediated effects. Ochsner J. 2013;13:214-223.
Lemmer B. The sleep-wake cycle and sleeping pills. Physiol Behav. 2007;90:285-293.
Gueye PN, Borron SW, Risede P, et al. Buprenorphine and midazolam act in combination to depress respiration in rats. Toxicol Sci. 2002;65:107-114.
Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med. 2015;49:493-501.
Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350:h2698.
Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760.
Hernandez I, He M, Brooks MM, Zhang Y. Exposure-response association between concurrent opioid and benzodiazepine use and risk of opioid-related overdose in Medicare part D beneficiaries. JAMA Netw Open. 2018;1:e180919.
US Department of Health and Human Services. The Surgeon General's call to end the opioid crisis. Accessed July 21, 2018. https://www.aafp.org/patient-care/public-health/pain-opioids/turn_the_tide.html
Centers For Disease Control and Prevention Public Health Service US Department of Health and Human Services. Guideline for prescribing opioids for chronic pain. J Pain Palliat Care Pharmacother. 2016;30:138-140.
US Food and Drug Administration. FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Accessed February 14, 2018. https://www.fda.gov/downloads/drugs/drugsafety/ucm518672.pdf
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Adult cancer pain 2018. Accessed May 4, 2018. https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf
Paice JA, Lacchetti C, Bruera E. Management of chronic pain in survivors of adult cancers: ASCO Clinical Practice Guideline Summary. J Clin Oncol. 2016;34:3325-3345. doi:10.1200/JCO.2016.68.5206
US Centers for Medicare and Medicaid Services. Concurrent use of opioids and benzodiazepines in a Medicare Part D population. Accessed February 4, 2018. https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Concurrent-Use-of-Opioids-and-Benzodiazepines-in-a-Medicare-Part-D-Population-CY-2015.pdf
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
Mayfield D, McLeod G, Hall P. The CAGE questionnaire: validation of a new alcoholism screening instrument. Am J Psychiatry. 1974;131:1121-1123.
Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S. The Memorial Delirium Assessment Scale. J Pain Symptom Manage. 1997;13:128-137.
Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care. 1991;7:6-9.
Bruera E, Dalal S, ed. The MD Anderson Supportive and Palliative Care Handbook. 5th ed. Houston, TX: The University of Texas Health Science Center; 2015.
ClinCalc.com. Equivalent benzodiazepine calculator. Accessed July 21, 2018. http://clincalc.com/About.aspx
Hui D, Shamieh O, Paiva CE, et al. Minimal clinically important differences in the Edmonton Symptom Assessment Scale in cancer patients: a prospective, multicenter study. Cancer. 2015;121:3027-3035.
Dev R, Parsons HA, Palla S, Palmer JL, Del Fabbro E, Bruera E. Undocumented alcoholism and its correlation with tobacco and illegal drug use in advanced cancer patients. Cancer. 2011;117:4551-4556.
Haider A, Zhukovsky DS, Meng YC, et al. Opioid prescription trends among patients with cancer referred to outpatient palliative care over a 6-year period. J Oncol Pract. 2017;13:e972-e981.
Pimentel LE, De La Cruz M, Wong A, Castro D, Bruera E. Snapshot of an outpatient supportive care center at a comprehensive cancer center. J Palliat Med. 2017;20:433-436.
Gomes T, Juurlink DN, Antoniou T, Mamdani MM, Paterson JM, van den Brink W. Gabapentin, opioids, and the risk of opioid-related death: a population-based nested case-control study. PLoS Med. 2017;14:e1002396.
Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol. 2017;27:1185-1215.